Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
CROME: Crizotinib for ROS1 and MET Activated Lung Cancer
NCT04084717Phase 2Completed
- Sponsor
- University Health Network
- Start
- Dec 2019
- Primary completion
- Dec 2024
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label trial of crizotinib in non-small cell lung cancer (NSCLC) (3 arms), sponsored by University Health Network. Primary endpoints: Response Rate at 5 years, Progression-free survival at 5 years and 4 more. Started Dec 2019; status: completed.
02
Drugs
crizotinib
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on NCT04084717.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04084717.